Chargement des cours...
Prévisions
L'objectif de cours moyen des analystes est de 5,47 € (+3 117,65 %). La médiane est de 5,47 € (+3 117,65 %).
| Acheter |
4 |
| Conserver |
1 |
| Vendre |
0 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Arcadia Biosciences secures $4 million through private placement
Arcadia Biosciences raised approximately $4 million in gross proceeds through a private placement, selling 3,883,496 common shares or prepaid warrants at $1.03 per share. The offering also included Series A-1 and A-2 investment options with an exercise price of $0.91; A-1 will be exercisable after shareholder approval, A-2 is immediately exercisable. H.C. Wainwright & Co. acted as sole placement agent; net proceeds are intended for working capital and general corporate purposes. The transaction is notable given a current market capitalization of $2.08 million; the company reports a current ratio of 3.79 and plans to file registration statements for resale. » Plus sur de.investing.com
Arcadia Biosciences secures $4 million through private placement
Arcadia Biosciences sold 3,883,496 common shares or prepaid warrants at a price of $1.03 each, generating gross proceeds of approximately $4 million. The transaction includes A‑1 and A‑2 warrants with an exercise price of $0.91; A‑1 warrants are valid for five years following shareholder approval, A‑2 warrants are immediately exercisable and expire 24 months after the registration statement becomes effective. H.C. Wainwright & Co. is acting as exclusive placement agent; the proceeds are intended for working capital and general corporate purposes, and the closing is expected subject to customary conditions. » Plus sur de.investing.com
Arcadia Biosciences dismisses Deloitte and appoints Ramirez Jimenez International as new auditor
Arcadia Biosciences dismissed Deloitte & Touche as its independent auditor effective March 30 and appointed Ramirez Jimenez International CPAs (RJI) to audit the quarter ended March 31, 2026 and the fiscal year ended December 31, 2026. Deloitte’s reports for 2024 and 2025 contained no adverse opinions but included an explanatory paragraph regarding going concern; the company disclosed material weaknesses in internal control over financial reporting for 2025, notably a lack of segregation of duties and deficient IT controls due to reduced staffing. Deloitte was authorized to provide RJI with information on the matters; Arcadia reports no disagreements with Deloitte. » Plus sur de.investing.com
Arcadia Biosciences stock rises after termination of Roosevelt deal
Arcadia Biosciences stock rose about 9% in pre-market trading after Roosevelt Resources terminated the securities exchange agreement dated December 4, 2024, as of December 24, 2025, in accordance with the contract. CEO T.J. Schaefer said the company will resume the review process for strategic alternatives and pointed to operational streamlining, cost reductions and growth of the coconut water brand Zola. The company still holds roughly 2.7 million common shares of Above Food Ingredients and expects additional consideration related to the sale of GoodWheat, which, together with the NASDAQ listing, should favor strategic transactions. » Plus sur de.investing.com
Arcadia Biosciences schedules annual general meeting for December 19, 2025
Arcadia Biosciences sets its 2025 annual general meeting for December 19 and says it will publish the time, location and agenda in the definitive proxy statement filed with the SEC. Shareholders must submit proposals or director nominations in writing by close of business on November 3, 2025. The company is keeping the annual meeting separate from a possible special meeting related to a Securities Exchange Agreement with Roosevelt Resources. In addition, CFO Mark Kawakami resigned effective September 12; Thomas J. Schaefer was appointed interim CFO and will take on the role in addition to his duties as CEO with no change to his compensation. Analysts see significant upside, with a $12 price target versus the current price of $4.14. » Plus sur de.investing.com
Données financières de l'entreprise
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 1,43 M | 28,83 % |
| Bénéfice brut | 758,37 k | 112,91 % |
| Bénéfice net | 1,55 M | 112,41 % |
| EBITDA | 1,55 M | 111,92 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 281,57 k € |
Nombre d'actions | 1,55 M |
Plus haut/bas sur 52 semaines | 3,53 € - 0,10 € |
| Dividendes | Non |
Bêta | 0,59 |
Ratio P/E | -0,02 |
Ratio PEG | 0,00 |
Ratio P/B | 0,50 |
Ratio P/S | 0,06 |
Profil de l'entreprise
Arcadia Biosciences, Inc. produit et commercialise des produits de santé et de bien-être à base de plantes aux États-Unis. Elle développe principalement des améliorations génétiques du blé afin d'optimiser la rentabilité des exploitations agricoles, en améliorant les performances des cultures au champ ainsi que leur valeur en tant qu'ingrédients alimentaires, leur intérêt pour les produits de santé et de bien-être, et leur viabilité pour des applications industrielles. La société a été constituée en 2002 et a son siège social à Davis, en Californie.
| Nom | Arcadia Biosciences |
| PDG | Thomas J. Schaefer |
| Siège social | Davis,
tx États-Unis |
| Site web | |
| Secteur | Consommation de base |
| Industrie | Produits alimentaires |
| Introduction en bourse | 15/05/2015 |
| Employés | 8 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | RKDA |
Frankfurt | 17DN.F |
München | 17DN.MU |